Midstage trials on the drug ABT-450 from Abbott Laboratories showed it helped suppress the hepatitis C virus and achieved a sustained response 24 weeks after treatment ended. ABT-450, which is in the same class as the recently approved HCV drugs Victrelis and Incivek, was given as part of a regimen that included other medications, some of which also are in development.

Related Summaries